MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.
Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be u...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5383023?pdf=render |
id |
doaj-01107c3c45bb4104af8c5963ace780a9 |
---|---|
record_format |
Article |
spelling |
doaj-01107c3c45bb4104af8c5963ace780a92020-11-25T01:48:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01124e017306010.1371/journal.pone.0173060MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.Simoni H AvansiniBeatriz Pereira de Sousa LimaRodrigo SecolinMarilza L SantosAna Carolina CoanAndré S VieiraFábio R TorresBenilton S CarvalhoMarina K M AlvimMárcia E MoritaClarissa L YasudaLuciana R Pimentel-SilvaDanyella B DoginiFabio RogerioFernando CendesIscia Lopes-CendesEpilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE.http://europepmc.org/articles/PMC5383023?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Simoni H Avansini Beatriz Pereira de Sousa Lima Rodrigo Secolin Marilza L Santos Ana Carolina Coan André S Vieira Fábio R Torres Benilton S Carvalho Marina K M Alvim Márcia E Morita Clarissa L Yasuda Luciana R Pimentel-Silva Danyella B Dogini Fabio Rogerio Fernando Cendes Iscia Lopes-Cendes |
spellingShingle |
Simoni H Avansini Beatriz Pereira de Sousa Lima Rodrigo Secolin Marilza L Santos Ana Carolina Coan André S Vieira Fábio R Torres Benilton S Carvalho Marina K M Alvim Márcia E Morita Clarissa L Yasuda Luciana R Pimentel-Silva Danyella B Dogini Fabio Rogerio Fernando Cendes Iscia Lopes-Cendes MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. PLoS ONE |
author_facet |
Simoni H Avansini Beatriz Pereira de Sousa Lima Rodrigo Secolin Marilza L Santos Ana Carolina Coan André S Vieira Fábio R Torres Benilton S Carvalho Marina K M Alvim Márcia E Morita Clarissa L Yasuda Luciana R Pimentel-Silva Danyella B Dogini Fabio Rogerio Fernando Cendes Iscia Lopes-Cendes |
author_sort |
Simoni H Avansini |
title |
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
title_short |
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
title_full |
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
title_fullStr |
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
title_full_unstemmed |
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
title_sort |
microrna hsa-mir-134 is a circulating biomarker for mesial temporal lobe epilepsy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE. |
url |
http://europepmc.org/articles/PMC5383023?pdf=render |
work_keys_str_mv |
AT simonihavansini micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT beatrizpereiradesousalima micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT rodrigosecolin micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT marilzalsantos micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT anacarolinacoan micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT andresvieira micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT fabiortorres micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT beniltonscarvalho micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT marinakmalvim micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT marciaemorita micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT clarissalyasuda micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT lucianarpimentelsilva micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT danyellabdogini micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT fabiorogerio micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT fernandocendes micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy AT iscialopescendes micrornahsamir134isacirculatingbiomarkerformesialtemporallobeepilepsy |
_version_ |
1725013094217809920 |